Are Peptides FDA Approved? The Complete Regulatory Guide for 2026

The Short Answer: Some Peptides Are FDA-Approved, Most Are Not

"Are peptides FDA-approved?" is one of the most common questions patients ask when considering peptide therapy — and one of the most frequently misunderstood. The answer is nuanced because "peptides" is not a single product but a broad category of molecules, and the regulatory status of each peptide depends on its specific approval history, manufacturing source, and intended use.

Here is the short version: Several peptides have full FDA approval as prescription drugs for specific medical indications. These include semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta), bremelanotide (Vyleesi), octreotide (Sandostatin), and others. When you obtain these peptides as brand-name products from a retail pharmacy with a valid prescription for their approved indication, you are using fully FDA-approved medications.

Many other peptides are not FDA-approved for any indication but are legally available through compounding pharmacies under the authority of the Federal Food, Drug, and Cosmetic Act's compounding exemptions (Sections 503A and 503B). These include widely used peptides like CJC-1295, Ipamorelin, BPC-157, TB-500, and others. They are legal to prescribe and compound when done in accordance with federal and state compounding regulations — but they have not undergone the full FDA approval process (Phase I through Phase III clinical trials, NDA submission, and formal FDA review).

A third category — and the source of the most confusion in 2026 — includes peptides that have been reclassified by the FDA through regulatory actions in 2025-2026 that changed their eligibility for compounding. Understanding these distinctions is essential for making informed decisions about your treatment and ensuring that your provider and pharmacy are operating within the law.

FDA-Approved Peptide Drugs: The Complete 2026 List

The following peptides have received full FDA approval as prescription drugs. This means they have completed rigorous clinical trials demonstrating safety and efficacy for their approved indications, have been reviewed and approved by the FDA, and are manufactured by pharmaceutical companies under strict cGMP (current Good Manufacturing Practice) standards.

GLP-1 Receptor Agonists

Brand Name	Active Peptide	FDA-Approved Indications	Year Approved
Ozempic	Semaglutide	Type 2 diabetes; cardiovascular risk reduction	2017
Wegovy	Semaglutide	Chronic weight management (BMI 30+ or 27+ with comorbidity)	2021
Rybelsus	Semaglutide (oral)	Type 2 diabetes	2019
Mounjaro	Tirzepatide	Type 2 diabetes	2022
Zepbound	Tirzepatide	Chronic weight management	2023
Victoza	Liraglutide	Type 2 diabetes	2010
Saxenda	Liraglutide	Chronic weight management	2014
Trulicity	Dulaglutide	Type 2 diabetes	2014

Growth Hormone and Related Peptides

Brand Name	Active Peptide	FDA-Approved Indications	Year Approved
Genotropin, Humatrope, Norditropin, etc.	Somatropin (recombinant human GH)	GH deficiency (pediatric and adult); Turner syndrome; chronic renal insufficiency; others	1987-present
Egrifta SV	Tesamorelin	HIV-associated lipodystrophy (excess abdominal fat)	2010
Sogroya	Somapacitan	Adult GH deficiency (once-weekly formulation)	2020
Skytrofa	Lonapegsomatropin	Pediatric GH deficiency (once-weekly)	2021

Other FDA-Approved Peptides

Brand Name	Active Peptide	FDA-Approved Indications
Vyleesi	Bremelanotide (PT-141)	Hypoactive sexual desire disorder (HSDD) in premenopausal women
Sandostatin / Mycapssa	Octreotide	Acromegaly; carcinoid tumors; VIPomas
Thyrogen	Thyrotropin alfa	Thyroid cancer diagnostic adjunct
Lupron / Eligard	Leuprolide	Prostate cancer; endometriosis; central precocious puberty
Scenesse	Afamelanotide	Erythropoietic protoporphyria (EPP)
Linzess	Linaclotide	IBS with constipation; chronic idiopathic constipation

This is not an exhaustive list — there are dozens of FDA-approved peptide drugs across oncology, endocrinology, immunology, and other specialties. The key point is that FDA approval is indication-specific: semaglutide is FDA-approved for type 2 diabetes and obesity, but it is not FDA-approved for anti-aging, cognitive enhancement, or body recomposition. When a physician prescribes an FDA-approved peptide for a use other than its approved indication, that constitutes "off-label" use — which is legal and common in medicine, but may affect insurance coverage and means that the specific use has not been formally reviewed by the FDA for safety and efficacy.

The 2025-2026 Reclassification: 14 Peptides Moved to Category 2

The most significant regulatory change affecting the peptide therapy industry in recent years occurred in 2025-2026 when the FDA completed a review of peptides commonly available through compounding pharmacies and reclassified 14 of them. This action — which had been anticipated since the FDA began its review in 2023 — moved these peptides from Category 1 (eligible for compounding) to Category 2 (not eligible for compounding under most circumstances), effectively restricting their availability through the compounding pharmacy pathway that had made them accessible to patients nationwide.

Understanding the Category System

To understand what reclassification means, you first need to understand the FDA's bulk drug substance categorization system. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are allowed to compound medications using "bulk drug substances" — raw pharmaceutical ingredients — provided those substances meet certain criteria. The FDA maintains lists that determine which substances are eligible:

• Category 1 — Eligible for Compounding: These bulk drug substances can be used by compounding pharmacies to prepare patient-specific (503A) or batch (503B) medications. To be in Category 1, the substance must be nominated, reviewed by the FDA, and determined to meet safety, quality, and clinical need criteria. Most peptides commonly available through compounding pharmacies prior to 2025 were in this category.
• Category 2 — Not Eligible for Compounding (with limited exceptions): These substances have been reviewed by the FDA and determined to not meet the criteria for compounding eligibility — typically because of safety concerns, quality control challenges, or the availability of FDA-approved alternatives. Compounding pharmacies generally cannot use Category 2 substances, though there are narrow exceptions for patient-specific medical needs documented by a prescriber.
• Category 3 — Under Review: These substances have been nominated for the compounding bulk drug substances list but have not yet been fully evaluated. Their status may change as the FDA completes its review.

The 14 Reclassified Peptides

The following peptides were moved from Category 1 to Category 2 during the 2025-2026 regulatory cycle. This list has been confirmed by FDA final rulemaking and is current as of April 2026:

Peptide	Common Use	FDA Rationale for Reclassification	Status (Apr 2026)
BPC-157	Tissue healing / recovery	Insufficient human safety data; quality control concerns	Category 2 (restricted)
AOD 9604	Fat loss	Failed Phase II trials; insufficient efficacy evidence	Category 2 (restricted)
DSIP (Delta Sleep Inducing Peptide)	Sleep enhancement	Lack of human clinical data	Category 2 (restricted)
Epitalon (Epithalon)	Anti-aging / telomere support	No human clinical trial data; safety concerns	Category 2 (restricted)
Follistatin 315 / 344	Myostatin inhibition / muscle growth	Insufficient human safety data; quality control issues	Category 2 (restricted)
GHK-Cu (Copper Peptide)	Wound healing / skin rejuvenation	Limited systemic safety data for injectable use	Category 2 (restricted)
KPV	Anti-inflammatory / gut health	No human clinical data	Category 2 (restricted)
Selank	Anxiolytic / cognitive enhancement	Approved in Russia only; no US clinical trials	Category 2 (restricted)
Semax	Cognitive enhancement / neuroprotection	Approved in Russia only; no US clinical trials	Category 2 (restricted)
Thymalin	Immune modulation	Insufficient human safety data	Category 2 (restricted)
Thymosin Alpha 1	Immune support	FDA-approved form (Zadaxin) exists internationally; compounding quality concerns	Category 2 (restricted)
Thymosin Beta 4 (TB-500)	Tissue repair / recovery	Insufficient human safety data; veterinary use concerns	Category 2 (restricted)
VIP (Vasoactive Intestinal Peptide)	Inflammatory conditions / CIRS	Quality control challenges; safety concerns at therapeutic doses	Category 2 (restricted)
Dihexa	Cognitive enhancement	No human clinical data; potent HGF mimetic with unknown long-term safety	Category 2 (restricted)

What Reclassification Actually Means for Patients

The practical impact of Category 2 reclassification depends on several factors:

For 503B outsourcing facilities: Category 2 peptides generally cannot be compounded by 503B pharmacies. These facilities rely on the ability to batch-produce medications, and Category 2 status removes the legal basis for doing so. Most 503B pharmacies stopped producing the affected peptides within weeks of the final reclassification.

For 503A compounding pharmacies: The situation is more nuanced. 503A pharmacies compound based on individual patient prescriptions, and some legal experts argue that the Category 2 designation does not entirely prohibit 503A compounding when a prescriber documents a specific patient need that cannot be met by a commercially available product. However, the legal risk is elevated, and many 503A pharmacies have voluntarily stopped compounding Category 2 peptides to avoid FDA enforcement action.

For patients currently on reclassified peptides: If you were using BPC-157, TB-500, or another reclassified peptide before the change, your provider should have discussed alternative options with you. In some cases, similar therapeutic goals can be achieved with peptides that remain in Category 1. In other cases, patients may need to consider FDA-approved alternatives or accept that the specific peptide is no longer available through legal domestic channels.

Legal Challenges and Ongoing Uncertainty

The reclassification has not gone unchallenged. Several industry groups, compounding pharmacy associations, and individual practitioners have filed legal challenges arguing that the FDA's process was procedurally flawed, that the Category 2 criteria were applied inconsistently, and that removing access to these peptides harms patients who were benefiting from them. As of April 2026, these legal challenges are working through the federal court system, and preliminary injunctions have been granted in some circuits that temporarily allow compounding to continue pending resolution.

The regulatory landscape is therefore in flux. Patients should work closely with their providers to understand the current legal status of any peptide they are using or considering, and should not assume that a peptide available six months ago is still legally available today — or that one currently restricted will remain so permanently.

Peptides That Remain Available Through Compounding (Category 1)

Despite the reclassification, many commonly used peptides remain in Category 1 and are legally available through compounding pharmacies. These include some of the most popular and well-studied peptides in clinical practice:

• CJC-1295 (with and without DAC): The most widely prescribed growth-hormone-releasing peptide remains fully available for compounding.
• Ipamorelin: The selective GHRP continues to be available and is commonly combined with CJC-1295.
• Sermorelin: With its long safety track record and prior FDA approval history, sermorelin remains firmly in Category 1.
• Tesamorelin: Available through compounding (in addition to the brand-name Egrifta) and remains in good regulatory standing.
• PT-141 / Bremelanotide: Available through compounding, though the FDA-approved brand (Vyleesi) also exists.
• GHRP-2 and GHRP-6: Older growth-hormone-releasing peptides that remain available.
• Semaglutide and tirzepatide: Available through compounding during documented shortages or for documented patient-specific needs, though subject to ongoing regulatory scrutiny as brand-name supply normalizes.

The continued Category 1 status of these peptides does not guarantee permanent availability — the FDA's review process is ongoing, and additional reclassifications could occur. However, peptides with stronger safety records, broader clinical evidence, and fewer quality control concerns are less likely to be reclassified.

Compounding Pharmacies: 503A vs. 503B Explained

Understanding the difference between 503A and 503B compounding pharmacies is essential for navigating the peptide landscape, because the regulatory framework, quality standards, and legal authorities differ significantly between these two categories.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies — the kind that have existed for over a century, preparing customized medications based on individual patient prescriptions. Key characteristics include:

• Patient-specific prescriptions required: Every compounded medication must be prepared in response to a valid prescription for an identified individual patient.
• State regulation: 503A pharmacies are primarily regulated by state boards of pharmacy. The FDA has limited (but not zero) oversight authority.
• No batch production: While pharmacies may prepare limited quantities in anticipation of prescription demand, large-scale batch production is not permitted.
• Pharmacist supervision: A licensed pharmacist must supervise all compounding activities.
• No FDA cGMP requirement: 503A pharmacies are not required to meet the same cGMP manufacturing standards as drug manufacturers, though they must comply with USP (United States Pharmacopeia) standards for compounding.
• Geographic limitations: Many states restrict 503A pharmacies from shipping compounded medications across state lines (though this varies by state and is enforced inconsistently).

503B Outsourcing Facilities

Section 503B was created by the Drug Quality and Security Act of 2013, enacted in response to a deadly meningitis outbreak caused by contaminated compounded steroids from a poorly regulated pharmacy. 503B outsourcing facilities represent a higher regulatory tier:

• No individual prescriptions required: 503B facilities can produce batch quantities of compounded medications without patient-specific prescriptions, for use by healthcare facilities and practitioners.
• Federal FDA oversight: 503B facilities must register with the FDA, submit to regular FDA inspections, and report adverse events directly to the FDA.
• cGMP compliance: 503B facilities must meet current Good Manufacturing Practice standards — the same quality framework that applies to pharmaceutical manufacturers.
• Interstate distribution: 503B facilities can legally distribute compounded medications across state lines.
• Adverse event reporting: Required to report serious adverse events to the FDA within 15 days.
• Third-party testing: Many 503B facilities voluntarily engage in third-party potency and sterility testing and provide certificates of analysis (COAs) for their products.

Which Is Better for Patients?

For injectable peptides, 503B outsourcing facilities are generally preferable because the FDA oversight, cGMP compliance, and inspection regimen provide stronger assurance of sterility and potency. The risk of a contaminated injectable medication is low with any licensed pharmacy, but it is lower with a 503B facility that undergoes regular FDA inspection.

That said, 503A pharmacies offer advantages in certain situations: they can prepare highly customized formulations (unique concentrations, combinations, or alternative vehicles), they may be more responsive to individual patient needs, and their pricing is often lower. For oral or topical peptide formulations where sterility is less critical, 503A pharmacies are generally a safe and cost-effective choice.

State-Level Peptide Regulations

Federal FDA regulation provides the baseline framework for peptide therapy, but state-level regulations add another layer of complexity. Pharmacy practice, prescribing authority, and compounding regulations are primarily governed at the state level, and significant variation exists across jurisdictions.

Prescribing Authority

In all 50 states, licensed physicians (MDs and DOs) can prescribe peptide therapies. However, the prescribing authority of other practitioners varies:

• Nurse practitioners (NPs): In approximately 27 states and Washington, D.C., NPs have full practice authority and can prescribe peptides independently. In the remaining states, NPs require a collaborative or supervisory agreement with a physician.
• Physician assistants (PAs): PAs can prescribe peptides in all states, but most require a supervisory agreement with a physician. The degree of supervision required varies from minimal (chart review) to direct (on-site physician).
• Naturopathic doctors (NDs): Prescribing authority for NDs varies dramatically. States like Arizona, California, Oregon, and Washington grant NDs broad prescribing authority including injectable medications. Other states do not license naturopathic physicians at all.

Telemedicine Prescribing

The pandemic-era expansion of telemedicine prescribing has been partially preserved but is evolving. As of April 2026, most states allow peptide therapy to be prescribed via telemedicine, but several states require at least one in-person visit before or within 90 days of the initial telemedicine prescription. Some states have specific restrictions on prescribing controlled substances or injectable medications via telemedicine. Patients using telemedicine peptide platforms should verify that the platform is licensed to practice in their state and that the prescriber meets their state's requirements.

States with Notable Peptide Restrictions

A few states have enacted additional restrictions on peptide therapy beyond the federal framework:

• New York: Stricter compounding regulations and more limited 503A pharmacy authority. Some peptides available in other states may not be available through New York-licensed pharmacies.
• California: Strong consumer protection regulations that require additional disclosures for compounded medications and restrict certain marketing claims by peptide therapy clinics.
• Florida: Home to a large number of peptide therapy clinics and compounding pharmacies, but also subject to periodic enforcement actions. The Florida Board of Pharmacy has been more active than most in auditing compounding pharmacies for compliance.

How to Verify Your Provider and Pharmacy Are Operating Legally

Given the regulatory complexity, patients have a responsibility to verify that their peptide therapy provider and pharmacy are operating within the law. This is not merely a theoretical concern — the FDA has issued dozens of warning letters to clinics and pharmacies selling adulterated, mislabeled, or illegally compounded peptide products in 2025-2026 alone.

Verifying Your Provider

1. Confirm their license: Every state maintains a publicly searchable database of licensed healthcare providers. Verify that your prescriber holds an active, unrestricted license in your state. For physicians, check the state medical board website. For NPs and PAs, check the state nursing or medical board. A valid license should be listed with the practitioner's name, license number, and any disciplinary actions.
2. Check for disciplinary actions: Look for any board actions, sanctions, or malpractice history. The NPDB (National Practitioner Data Bank) is not publicly searchable, but state medical board websites typically list formal disciplinary actions.
3. Verify DEA registration (if applicable): While most peptides are not controlled substances, some clinics that prescribe a broader range of medications should hold a valid DEA registration. The DEA's registration verification tool is available at deadiversion.usdoj.gov.
4. Ask about their training and experience: Peptide therapy is a specialized area that most medical schools do not cover in depth. Ask whether your provider has completed continuing medical education (CME) in peptide therapy, hormone optimization, or anti-aging medicine. Certifications from organizations like A4M (American Academy of Anti-Aging Medicine) or AMMG (Age Management Medicine Group) indicate specialized training, though they are not required for legal prescribing.

Verifying Your Pharmacy

1. Confirm the pharmacy type (503A or 503B): Ask the pharmacy directly or check the FDA's list of registered 503B outsourcing facilities at fda.gov. If the pharmacy claims to be a 503B facility, it should appear on this list.
2. Check the state pharmacy license: All compounding pharmacies must hold a valid license from their state board of pharmacy. Most state boards maintain searchable online databases where you can verify license status and check for any disciplinary actions or compliance issues.
3. Request certificates of analysis (COAs): A reputable pharmacy should be willing to provide a COA for any peptide product, showing the results of potency testing, sterility testing (for injectables), and endotoxin testing. If a pharmacy cannot or will not provide a COA, consider this a significant red flag.
4. Check FDA inspection history (503B): For 503B outsourcing facilities, FDA inspection reports (Form 483s) are available through Freedom of Information Act requests and are sometimes published on the FDA website. A recent inspection with no significant findings is a positive indicator.
5. Verify PCAB accreditation (optional but positive): The Pharmacy Compounding Accreditation Board (PCAB) provides voluntary accreditation that indicates compliance with higher-than-minimum quality standards. PCAB-accredited pharmacies undergo rigorous inspections and maintain quality management systems.

Red Flags That Suggest Illegal or Unsafe Operations

• No prescription required: Any entity selling peptides for human use without requiring a prescription from a licensed provider is operating illegally. Peptides are not dietary supplements (though some are deceptively marketed as such), and selling them for injection without a prescription violates federal and state law.
• "Research use only" disclaimers: Websites that sell peptides labeled "for research use only" or "not for human consumption" are operating in a legal gray area designed to avoid FDA oversight. These products have not been tested for sterility, potency, or purity to pharmaceutical standards, and using them carries genuine risk.
• Overseas sourcing: Peptides sourced from overseas manufacturers (particularly from certain countries with weak pharmaceutical regulation) carry significant risks of contamination, mislabeling, and inconsistent potency. A legitimate US compounding pharmacy should source raw materials from FDA-inspected or cGMP-certified suppliers.
• No physical address or phone number: A legitimate pharmacy should have a verifiable physical location and phone number. An online-only operation with no physical presence and only an email contact is a red flag.
• Claims of FDA approval for non-approved peptides: If a provider or pharmacy claims that CJC-1295, BPC-157, or other non-FDA-approved peptides are "FDA-approved," they are either uninformed or deliberately misleading. These peptides may be legally available through compounding, but that is not the same as FDA approval.

Understanding Off-Label Prescribing

A significant portion of peptide therapy involves off-label prescribing — the practice of prescribing an FDA-approved medication for a use, dose, or patient population that was not specifically studied in the clinical trials that led to FDA approval. Off-label prescribing is legal, ethical, and extremely common in medicine: an estimated 20-30% of all prescriptions in the United States are off-label.

Examples of off-label peptide prescribing include:

• Prescribing semaglutide at doses below or above the FDA-approved range based on individual patient response
• Prescribing tesamorelin for non-HIV patients with visceral adiposity
• Prescribing bremelanotide (PT-141) for men with sexual dysfunction (FDA-approved only for women with HSDD)
• Using FDA-approved peptides in combination with other peptides in ways not studied in clinical trials

Off-label prescribing is legal because the FDA regulates drug marketing (what manufacturers can say about their products), not the practice of medicine (what physicians can prescribe). However, patients should be informed when their use is off-label, understand that the specific use has not been formally reviewed by the FDA, and be aware that insurance coverage is less likely for off-label prescriptions.

What the Future Holds: Regulatory Trends to Watch

The peptide regulatory landscape will continue to evolve through 2026 and beyond. Here are the key trends that patients and providers should monitor:

• Ongoing Category reviews: The FDA has not completed its review of all nominated peptides. Additional reclassifications are possible in 2026-2027, which could affect the availability of currently Category 1 peptides.
• Compounded GLP-1 enforcement: As brand-name semaglutide and tirzepatide supply stabilizes, the FDA is expected to take a harder line on compounded versions. The legal battles between compounding pharmacy advocates and the FDA will shape the availability of compounded GLP-1 agonists for years to come.
• Congressional action: Several bills introduced in Congress in 2025-2026 aim to protect patient access to compounded peptides, define clearer criteria for Category 2 reclassification, and establish a formal pathway for peptides that do not meet the full NDA requirements but have sufficient safety data for continued compounding. Whether any of these bills pass remains uncertain.
• State-level initiatives: Some states are considering legislation to protect patient access to compounded peptides regardless of federal Category 2 designations. The legal viability of such state-level protections against federal regulation is untested and uncertain.
• New FDA approvals: Several peptides currently in Phase II/III clinical trials could receive FDA approval in 2026-2028, which would create new brand-name options but could also further restrict compounding of those molecules (since the FDA generally takes the position that compounding of commercially available drugs is only justified during shortages).

Practical Guidance for Patients in 2026

Given the complexity and evolving nature of peptide regulation, here is a practical summary of how to navigate the landscape responsibly:

1. Work with a licensed provider: Always obtain peptide therapy through a licensed healthcare provider who can evaluate your medical history, order appropriate lab work, monitor your response, and adjust your protocol as needed. Self-administering peptides obtained from unregulated sources is both illegal and unsafe.
2. Use regulated pharmacies: Obtain your peptides from licensed 503A or 503B compounding pharmacies or retail pharmacies dispensing brand-name products. Never purchase peptides from websites that do not require a prescription or that label their products "for research use only."
3. Ask about regulatory status: Before starting any peptide, ask your provider about its current regulatory status. Is it FDA-approved? If so, for what indication? Is it Category 1 or Category 2? Is it being compounded, and if so, is the pharmacy a 503A or 503B facility?
4. Stay informed: Regulatory changes can affect your treatment. Ask your provider to notify you of any changes that affect the peptides you are using, and check resources like the PeptideProbe directory for updated regulatory information.
5. Keep documentation: Maintain copies of your prescriptions, lab results, and pharmacy receipts. In the event of regulatory changes or insurance disputes, having a clear paper trail of medically supervised treatment is important.
6. Report adverse events: If you experience a serious adverse event from a peptide therapy, report it to the FDA's MedWatch program and to your state board of pharmacy. Adverse event reporting is a critical component of the safety monitoring system that keeps the compounding industry accountable.

The Bottom Line

The regulatory status of peptide therapy in 2026 is complex but navigable. Several important peptides are fully FDA-approved and available through standard pharmacy channels. Many others remain legally available through compounding pharmacies under Category 1 status. The 2025-2026 reclassification has restricted 14 peptides, but the most widely used growth-hormone-releasing peptides (CJC-1295, Ipamorelin, Sermorelin) are unaffected. Legal challenges and legislative efforts may restore access to some reclassified peptides in the future.

The most important thing patients can do is work with licensed, knowledgeable providers and regulated pharmacies. The regulatory framework — however imperfect — exists to protect patient safety. Operating within that framework does not guarantee a perfect outcome, but it dramatically reduces the risks associated with unregulated, untested, or contaminated products.

Use the PeptideProbe directory to find licensed peptide therapy providers in your area. Our listings are verified for active medical licenses, and we provide information about each clinic's prescribing approach, pharmacy partnerships, and regulatory compliance.

Medical Disclaimer: This article is for informational purposes only and does not constitute legal or medical advice. Regulatory information is current as of April 2026 but is subject to change. The legal status of specific peptides may vary by jurisdiction and may have changed since publication. Always consult with a licensed healthcare provider and, if necessary, a healthcare attorney for guidance specific to your situation. This article does not encourage or endorse the use of any substance in violation of federal or state law.